Upon completion of this activity, participants should be able to:

• Review foundational pharmacogenomics principles.
• Describe what to consider when implementing pharmacogenomics in clinical practice.
• Apply pharmacogenomics test results to make recommendations for an individualized medication management plan.
• Identify barriers and challenges of considering pharmacogenomics in patient care.

Attendance at any Mayo Clinic course does not indicate or guarantee competence or proficiency in the skills, knowledge or performance of any care or procedure(s) which may be discussed or taught in this course.

Program : 

Integrating Pharmacogenomics into Clinical Practice

Pharmacogenomics (PGx) Principles and Concepts

Pharmacogenomics 101: An Introduction to Foundational Concepts
Christopher T. Grilli, Pharm.D., R.Ph., M.B.A.

Variability and Pharmacokinetic Principles
Wayne T. Nicholson, M.D., Pharm.D.

Sex, Drugs, and Genetic Variation
Ann M. Moyer, M.D., Ph.D.

Pharmacogenomics’ Emerging Role
Richard Weinshilboum, M.D.

Pharmacogenomics: Discovery and Translation
Liewei Wang, M.D., Ph.D.

Untangling the Polypharmacy Burden with Pharmacogenomics Testing
Eric T. Matey, Pharm.D., R.Ph.

Pharmacogenomics (PGx) Rules and Regulations

Legal Implications of Pharmacogenomics Testing
Sharon C. Zehe, J.D.

PGx from a Patient Perspective: GINA & Other Important Questions
Teresa M. Kruisselbrink, M.S., CGC, LCGC

Pharmacogenomics (PGx) Clinical Laboratory Testing

Clinical Laboratory Testing in PGx: “the Lab” 101
Ann M. Moyer, M.D., Ph.D.

Clinical Laboratory Testing in PGx: Targeting Genotyping Technology
Ann M. Moyer, M.D., Ph.D.

Clinical Laboratory Testing in PGx: “Sequencing”
Ann M. Moyer, M.D., Ph.D.

Clinical Laboratory testing in PGx: “Reporting”
Ann M. Moyer, M.D., Ph.D.

Pharmacogenomics in Practice: General Principles

Pharmacogenomics Testing: Role in Clinical Medicine
Denise M. Dupras, M.D., Ph.D.

10 Considerations for the Clinician Applying Pharmacogenomics to Practice
Wayne T. Nicholson, M.D., Pharm.D.

Polypharmacy and PGx: Multi-Drug, Herbal/Dietary Supplement Case Study
Michael J. Schuh, Pharm.D., R.Ph.

Utilizing National Pharmacogenomics Guidelines and Other Resources
Jessica A. Wright, Pharm.D., R.Ph.

Case Review: From My Practice to Yours
Sheena K. Crosby, Pharm.D., R.Ph.

Pharmacogenomics in Practice: Panel Discussions

Pharmacogenomics from the Patient Perspective
Darryl S. Chutka, M.D. (Moderator), Matthew J. Ferber, Ph.D., Karen M. Meagher, Ph.D. & Sharon C. Zehe, J.D.

Pharmacogenomics from the Clinician Perspective
Matthew E. Bernard, M.D., Jennifer A. Bold APRN, C.N.P., D.N.P., Darryl S. Chutka, M.D. (Moderator) & Paul Y. Takahashi, M.D.

Pharmacogenomics from the Pharmacy Perspective
Christopher Grilli, Pharm.D., R.Ph.,M.B.A. (Moderator), Ashley D. Ebenhoh, Pharm.D., R.Ph., & Razan M. El Melik, Pharm.D., R.Ph.

Education for the Multidisciplinary Team
Jyothsna (Jo) Giri, M.D., M.B.A., Christopher M. Kohler, M.A.N., R.N., N.E.-B.C., Tammy M. McAllister, M.A. (Moderator), & Lance J. Oyen, Pharm.D., R.Ph.

Pharmacogenomics in Practice: Analgesic/Anesthesia

Pharmacogenomics of Analgesics
Wayne (Nick) T. Nicholson, M.D., Pharm.D.

Pharmacogenomics: Anesthesia
Timothy B. Curry, M.D., Ph.D.

Pharmacogenomics in Practice: Psychiatry

Pharmacogenomics of Antidepressants
Adrijana Kekic, Pharm.D., R.Ph.

Case Review: Antidepressants, SSRIs (Sertraline) and SNRIs
Adrijana Kekic, Pharm.D., R.Ph.

Psychiatric Pharmacogenomics: Panel Discussion
Darryl S. Chutka, M.D. (Moderator), Eric T. Matey, Pharm.D., R.Ph., Denise M. Dupras, M.D., Ph.D., Richard Weinshilboum, M.D.

Pharmacogenomics in Practice: Cardiology/GI

Pharmacogenomics in Cardiovascular Disease
Naveen L. Pereira, M.D.

Warfarin & Statin Pharmacogenomics Cases
Jan A. Anderson, Pharm.D., R.Ph.

PGx use in Patients with Gastroesophageal Reflux Disease
Imad Absah, M.D.

Pharmacogenomics in Practice: Oncology/Hematology

Pharmacogenomics in Oncology
Eric J. Yancey, Pharm.D., R.Ph.

Why is CYP2D6 Genotyping Ready for Primetime: Association of CYP2D6 Genotype and Breast Cancer Outcome from Large Trials
Matthew P. Goetz, M.D.

Dihydropyrimidine Dehydrogenase (DPD) Deficiency: Implications for 5-Fluorouracil (Capecitabine) Treatment
Robert B. Diasio, M.D.

Belinostat and UGT1A Polymorphism
N. Nora Bennani, M.D.

Case: Oncology
Caren L. Hughes, Pharm.D., R.Ph.

Case Study: Thiopurines/TPMT and NUDT15 in Clinical Practice
Edward V. Loftus, Jr. M.D.

Pharmacogenomics in Practice: Transplant, Infectious Disease, Immunology, Urology

Pharmacogenomics for Transplant Patients: Immunosuppression and Beyond
Mira T. Keddis, M.D.

Pharmacogenomics: Challenges with Hematopoietic Stem Cell and Liver Transplantation
John Logan Black, M.D.

Voriconazole Case
Christopher J. Arendt, Pharm.D., R.Ph.

Using Pharmacogenomics to Predict Drug Hypersensitivity
John D. Zeuli, Pharm.D., R.Ph.

HLA and Hypersensitivity
Jyothsna (Jo) Giri, M.D., M.B.A.

Gout Management: Role of Pharmacogenomics
Denise M. Dupras, M.D., Ph.D.

Pharmacogenomics Implementation

Significant Pharmacogenomics Cases
Heather H. Randles, Pharm.D., R.Ph.

Developing an Individualized Medication Plan
Eric T. Matey, Pharm.D., R.Ph.